PMC:3431878 / 12343-14181 JSONTXT

{"project":"2_test","denotations":[{"id":"22949880-8685601-50810688","span":{"begin":237,"end":239},"obj":"8685601"},{"id":"22949880-12595747-50810689","span":{"begin":355,"end":357},"obj":"12595747"},{"id":"22949880-19321947-50810690","span":{"begin":358,"end":360},"obj":"19321947"},{"id":"22949880-12595747-50810691","span":{"begin":526,"end":528},"obj":"12595747"},{"id":"22949880-8685601-50810692","span":{"begin":725,"end":727},"obj":"8685601"},{"id":"22949880-12595747-50810693","span":{"begin":908,"end":910},"obj":"12595747"},{"id":"22949880-12595747-50810694","span":{"begin":1250,"end":1252},"obj":"12595747"},{"id":"22949880-12595747-50810695","span":{"begin":1439,"end":1441},"obj":"12595747"},{"id":"22949880-12595747-50810696","span":{"begin":1834,"end":1836},"obj":"12595747"},{"id":"T81450","span":{"begin":237,"end":239},"obj":"8685601"},{"id":"T43558","span":{"begin":355,"end":357},"obj":"12595747"},{"id":"T18817","span":{"begin":358,"end":360},"obj":"19321947"},{"id":"T99324","span":{"begin":526,"end":528},"obj":"12595747"},{"id":"T51871","span":{"begin":725,"end":727},"obj":"8685601"},{"id":"T67956","span":{"begin":908,"end":910},"obj":"12595747"},{"id":"T28911","span":{"begin":1250,"end":1252},"obj":"12595747"},{"id":"T7649","span":{"begin":1439,"end":1441},"obj":"12595747"},{"id":"T75535","span":{"begin":1834,"end":1836},"obj":"12595747"}],"text":"Numerous antibodies have been generated against CA125 since the initial discovery in 1981. These antibodies are classified as OC125-like (group A), M11-like (group B) or OV197 (group C) depending on the antigenic determinant recognized [31]. These antibodies are further subdivided into groups A1–A4 (OC125-like), B1/B2 (M11-like) and C1/C2 (OV197-like) [32,33]. It is important to note that although there are two antibodies classified as OV197-like, the antigenic recognition behavior of OV197 is different to that of 7C12 [32]. Extensive investigation into the epitope recognition of the different class antibodies to CA125 has been performed by the International Society of Oncology and Biomarkers (ISOBM) TD-1 workshop [31]. Cross-inhibition and immunometric assays have been used to examine the various epitopes on CA125 isolated from normal abdominal fluids, cervical mucus, cell culture and ascites [32]. From this the importance of antibody class combinations for accurate detection of CA125 was revealed. Furthermore, differential antibody interaction with CA125 isolated in low-molecular-weight fractions was also highlighted. Here, different immunometric assay combinations resulted in different CA125 activity levels in those fractions [32]. It was noted that the difference in assay results could be due to the different behavior of the antibody combinations towards the low-molecular-weight fractions of CA125 preparations [32]. Conversely, fractions containing high-molecular-weight CA125 yielded similar CA125 activity levels regardless of the antibody pair used in the immune-assay. As high-molecular-weight forms of CA125 are the major component in most samples this phenomenon should, therefore, not interfere with the immunometric assays even if the standards used do not have the same composition as the sample [32]."}